Originating from our nucleos(t)ide discovery capabilities, bemnifosbuvir (AT-527) is an oral direct-acting antiviral being evaluated in SUNRISE-3, a global Phase 3 registrational trial for the treatment of COVID-19. In March 2024, Atea completed enrollment of SUNRISE-3 with 2,221 high-risk patients in the bemnifosbuvir monotherapy cohort and 74 patients in the combination cohort. Bemnifosbuvir targets the SARS-CoV-2 RNA polymerase (nsp12), a highly conserved enzyme that is unlikely to change as the virus mutates and new variants continue to emerge. This enzyme is responsible for both transcription and replication of SARS-CoV-2. Bemnifosbuvir has a unique mechanism of action, with dual targets consisting of inhibition of RNA dependent RNA polymerase (RdRp) and nucleotityltransferase (NiRAN) inhibition, which has the potential to create a high barrier to resistance.
In addition to COVID-19, bemnifosbuvir is also being developed in a Phase 2 clinical trial in combination with ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). As single agents, both bemnifosbuvir and ruzasvir have demonstrated potent pan-genotypic antiviral activity against HCV.
Atea is a clinical stage biopharmaceutical company working to address unmet medical needs with innovative oral antiviral therapies.
COVID-19
Long-term multibillion dollar market opportunity of approximately $4-5+ billion annually
Hepatitis C (HCV)
HCV continues to be a healthcare crisis with number of new cases exceeding cures— global market in 2023 was approximately >$3 billion in net sales
COVID-19
Completing global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients
Hepatitis C (HCV)
Executing global Phase 2 combination trial for bemnifosbuvir + ruzasvir in HCV patients
Leveraging our deep understanding of antiviral drug development, medicinal chemistry, biology, biochemistry and virology, we are discovering and developing novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of serious viral diseases. Currently, we are focused on the development of orally-available direct-acting antiviral agents for serious viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, and HCV.
Updates on bemnifosbuvir, other Atea product candidates and company news.
97% SVR12 Rate Observed with 8 Weeks of Treatment in Lead-In Cohort of HCV-Infected Patients in Ongoing Phase 2 Clinical Study EASL Presentations Continue to Support Best-in-Class Potential with High Antiviral Potency, Short Treatment Duration, Low Risk of Drug Interaction and High Barrier to
BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief
Presentations to Include New Antiviral Efficacy Results, Including SVR12 Data, from Lead-In Cohort of Ongoing Phase 2 HCV Trial Data Also Highlight the High Prevalence of Pre-Existing NS5A Resistance-Associated Substitutions (RAS) Detected in HCV-infected Patients BOSTON, May 22, 2024 (GLOBE
Atea is a clinical-stage biopharmaceutical company committed to addressing unmet medical needs through novel antiviral treatments.
Copyright © 2023 By Atea Pharmaceuticals. All Rights Reserved. Privacy Policy | Terms of Use